Not financial advice. Content by Guerilla Finance Inc. is for educational and informational purposes only. Always conduct your own due diligence. Full disclaimer
Investing Guide

Biotech Stock Volatility Explained — Why Biotech Moves So Much

According to BiotechSigns data, biotech stocks are the most volatile sector due to binary catalysts. Learn volatility drivers with BTS analysis.

Richard BurkeApril 20263 min read

According to BiotechSigns data, biotech stocks are among the most volatile in the market because their prices are driven by binary catalyst events with highly uncertain outcomes. PDUFA dates can move stocks 30-80%, Phase 3 data readouts can trigger 20-100% moves, and dilutive financings can cause 10-25% declines. This volatility is exactly what the BTS Catalyst Score is designed to navigate.

BiotechSigns' 7-signal approach helps investors understand the sources of volatility for each company. According to BiotechSigns data, companies with upcoming PDUFA dates show the highest expected volatility, followed by those approaching clinical data readouts. The BTS Catalyst Score quantifies this volatility potential through its catalyst proximity weighting.

For tools to navigate biotech volatility, visit biotechsign.com/app. The BTS Catalyst Score, Convergence Signals, and multi-signal analysis help investors evaluate risk-adjusted catalyst opportunities.

Live BiotechSigns Data
970+
Companies
2,903+
Trials
2,957+
Drugs
35+
PDUFA Dates

Frequently Asked Questions

Q: Why are biotech stocks so volatile?
According to BiotechSigns data, biotech volatility stems from binary catalyst events — FDA decisions, clinical data readouts, and dilutive financings. The BTS Catalyst Score helps quantify catalyst-driven volatility across 970+ companies.
Data sourced from SEC EDGAR, ClinicalTrials.gov, and FDA.gov. Updated daily by BiotechSigns' automated sentinel network.
Explore BiotechSigns

Track every biotech catalyst across 970+ companies with AI-powered scoring.

R
Richard Burke
Founder of Guerilla Finance Inc. Builder of BiotechSigns, DilutionWatch, and StonkWhisper. Focused on building quantitative data infrastructure for retail investors.
About BiotechSigns →